Semaglutide may lead to missed periods in some individuals, particularly if they experience significant weight loss while on the medication
2 y Data from participants without events of interest were censored at the end of their in-trial period
GLP-1s, a class of drugs used to treat type 2 diabetes, obesity, cardiovascular disease, and other conditions, have exploded in popularity in recent years due to their demonstrated effectiveness, but are often not covered by insurance, particularly for the treatment of obesity
The treatment also led to improvements in waist circumference, waist-to-hip ratio, and body image, without affecting blood sugar levels or causing major side effects
But the story does not end at 68 weeks
: